Jump Financial LLC Takes $71,000 Position in ProQR Therapeutics (NASDAQ:PRQR)

Jump Financial LLC acquired a new position in shares of ProQR Therapeutics (NASDAQ:PRQR) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 26,702 shares of the biopharmaceutical company’s stock, valued at approximately $71,000.

Several other institutional investors have also recently modified their holdings of PRQR. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $32,000. ADAR1 Capital Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $54,000. Ballentine Partners LLC purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $61,000. Prudential Financial Inc. grew its stake in ProQR Therapeutics by 109.1% in the 4th quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 14,400 shares during the period. Finally, PNC Financial Services Group Inc. purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $77,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Price Performance

Shares of PRQR stock opened at $1.54 on Tuesday. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The firm has a market capitalization of $162.03 million, a P/E ratio of -4.81 and a beta of 0.25. The company’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $2.50.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price for the company. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Finally, HC Wainwright boosted their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, ProQR Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).